Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Triple-Negative Breast Carcinoma
Interventions: DRUG: PVX-410
Sponsor: OncoPep, Inc.